Management of de novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and the role of Radiation Therapy: A Consensus by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).

MLA

Lancia, Andrea, et al. “Management of de Novo Metastatic Hormone-Sensitive Prostate Cancer (MHSPC) and the Role of Radiation Therapy: A Consensus by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).” Practical Radiation Oncology, Oct. 2024. EBSCOhost, https://doi.org/10.1016/j.prro.2024.10.007.

APA

Lancia, A., Alitto, A. R., Pappagallo, G., Ciurlia, E., Francolini, G., D’Angelillo, R., Fersino, S., Levra, N. G., Jereczek-Fossa, B. A., Magli, A., Pasqualetti, F., Reali, A., Spatola, C., & Triggiani, L. (2024). Management of de novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and the role of Radiation Therapy: A Consensus by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2024.10.007

Chicago

Lancia, Andrea, Anna Rita Alitto, Giovanni Pappagallo, Elisa Ciurlia, Giulio Francolini, Rolando D’Angelillo, Sergio Fersino, et al. 2024. “Management of de Novo Metastatic Hormone-Sensitive Prostate Cancer (MHSPC) and the Role of Radiation Therapy: A Consensus by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).” Practical Radiation Oncology, October. doi:10.1016/j.prro.2024.10.007.